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 Abstract - The treatment of degenerative hip 
joint disease involves modern operative techniques 
and the use of prosthetic devices individualized on 
each patient. Being a surgery of considerable 
importance, great attention is always given by the 
anaesthesiologist to postoperative analgesia. In 
general, our goal is to limit the doses of NSAIDs, 
known to be associated with haemostasis 
interference and alteration of gastrointestinal 
apparatus; component of our baseline analgesic 
protocols after arthroplasty is morphine given 
parenterally. In order to steadily improve analgesic 
techniques, which directly impact on patient 
outcome, we experimented the use of a continuous 
infusion of magnesium sulphate during subarachnoid 
anaesthesia. Magnesium sulphate is the drug of 
choice in case of eclampsia, and pre-eclampsia (for 
the risk of evolution in eclampsia). According to the 
most recent findings, this drug has also analgesic 
properties: its use as an adjunct to analgesia is based 
on a non-competitive antagonism towards the 
NMDA receptor and on the blocking of calcium 
channels: these properties prevent the mechanisms of 
central sensitization due to nociceptive stimulation 
of peripheral nerves. 
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I.  INTRODUCTION 
 
 The treatment of degenerative hip joint disease 
involves modern operative techniques and the use of 
prosthetic devices individualized on each patient [1,2,3]. 
 In recent years the hip surgery has evolved: the 
surgeon has increasingly refined surgical techniques that 
allow him to safely perform hip arthroplasty without 
altering anatomical structures. The indications have 
expanded, the average age of patients undergoing surgery 
has reduced, while life expectancy has considerably 
increased, thus creating to the surgeon problems sometime 
difficult to solve [4]. 
The aim of the intervention of hip replacement is 
to recreate a not painful, stable joint, which allows the 
patients to carry out their daily activities, but it must last 
over time and determine no biological intolerance.  
The hip surgery can be classified into three types: the total 
replacement or arthroplasty, in which the surgeon 
intervene on both articular components, femoral and 
acetabular; partial replacement, commonly indicated with 
the term endoprosthesis, reserved for the treatment of 
medial fractures of the neck of the femur, which allows to 
preserve the acetabulum; the revision, which is the 
replacement of a previously implanted device. 
 The diseases that may require hip arthroplasty 
can be divided into elective indication pathologies 
(primary arthrosis and secondary trauma in advanced 
stages, rheumatoid arthritis, aseptic osteonecrosis of the 
femoral head, hip dysplasia, ankylosing spondylitis, 
psoriatic arthritis, fracture of the medial femoral neck at 
the age of 60 years, secondary tumour lesions), and 
indication (juvenile rheumatoid arthritis, Paget's disease, 
bone tumours primitive medial femoral neck fracture in 
aged less than 60 years, bone tuberculosis, osteomyelitis, 
results of arthrodesis, dysplasia, acetabular fractures). 
All these causes alter the structures of the hip 
causing disability with pain, impotence and lameness. 
Being a surgery of considerable importance, great 
attention is always given by the anaesthesiologist to 
postoperative analgesia: in this field, the knowledge is 
constantly evolving, as evidenced in literature [5].  
In general, our goal is to limit the doses of 
NSAIDs, known to be associated with haemostasis 
interference and alteration of gastrointestinal apparatus; 
component of our baseline analgesic protocols after 
arthroplasty is morphine given parenterally.  
In order to steadily improve analgesic techniques, 
which directly impact on patient outcome, we 
experimented the use of a continuous infusion of 
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magnesium sulphate during subarachnoid anaesthesia 
[6,7].  
Magnesium sulphate is the drug of choice in case 
of eclampsia [8-10] (for the prevention of recurrent 
seizures), and pre-eclampsia (for the risk of evolution in 
eclampsia). According to the most recent findings [11,12], 
this drug has also analgesic properties: its use as an 
adjunct to analgesia is based on a noncompetitive 
antagonism towards the NMDA receptor [13] and on the 
blocking of calcium channels [14]: these properties 
prevent the mechanisms of central sensitization due to 
nociceptive stimulation of peripheral nerves [15]. 
 The purpose of this study was to evaluate the 
effect of the intravenous infusion of magnesium sulphate 
during spinal anaesthesia on the quality of analgesia and 
consumption of analgesics in the first 24 h after hip 
replacement surgery. 
 
  II.  METHODOLOGY 
 
 This controlled-randomized, double-blind trial 
was conducted in the months of January, February, March 
2012, on 12 patients referred to the Department of 
Orthopaedics and Traumatology of our AOU, who had an 
indication to perform hip replacement in spinal 
anaesthesia. These patients were informed of the current 
study and was collected their informed consent. It was 
also explained to them the proper functioning of the VAS 
(visual analogue scale of 10 cm where 0 cm = no pain, 10 
cm = worst pain imaginable). 
Inclusion criteria: patients ASA I-II, aged up to 
70 years, candidates for elective total hip replacement. 
Exclusion criteria: heart diseases, hypermagnesaemia, 
known hypersensitivity to magnesium sulphate, previous 
treatment with calcium channel blockers, all types of heart 
block, no predictors of intermediate or higher cardiac risk, 
acute or chronic kidney failure, liver or neuromuscular 
disease, abuse of opioids or analgesics. 
The anthropometric parameters of the patients  
were: 1.70 m10 cm of height, 70 kg ± 20kg of weight in 
the two groups, the mean values were similar (1.68 m and 
73kg MS group, group SI 1.72 m and 68 kg). Given the 
strict criteria of inclusion and exclusion, the groups were 
found to be homogeneous. 
The data were processed at the end of the study, 
calculating mean and standard deviation of the VAS and 
analgesic consumption, then compared by statistical 
analysis with T-student test (significance level p <0.01). 
Patients were randomized into 2 groups of 6 
elements each one: all patients received premedication 
with midazolam 0.03 mg / kg, then we performed spinal 
anaesthesia in the sitting position at the level  L2/L3 with 
a spinal 27 gauge Whitacre needle, using hyperbaric 
bupivacaine 0,5%;standard monitoring, ECG/SpO2 and 
non-invasive blood pressure, were carried out.  
All patients received 500 ml Ringer's lactate 
solution in 15 minutes, to counteract hypotension and the 
possible negative inotropic effect of the bolus magnesium 
sulphate. 
Immediately after the injection of the local 
anaesthetic, GROUP MS received 50 mg / kg of MgSO4 
in 15 min and then 15 mg / kg / h until the end of the 
surgical procedure, while the control group received the 
same volume of isotonic saline for the same period of 
time. 
In the case of bradycardia (HR lower than 45 
bpm) atropine was administered in boluses of 0.2 mg; in 
case of hypotension (SBP lower than 90 mmHg or 20% 
decrease of the baseline value) 5 mg of ephedrine iv were 
given.  
The average time of the procedure was 100 
minutes (60 min-120 min). It has never been necessary to 
convert the surgery under general anaesthesia. 
After the surgical procedure 90 mg of ketorolac 
in 24 hours via iv elastomeric infusor at the rate of 2ml / h 
were administered to both groups. If necessary (VAS 6 or 
more), paracetamol 1 g iv. was administered as an 
analgesic rescue in the postoperative period.  
We subsequently evaluated for 24 h the 
following parameters: 
-Pain (VAS) at the time T1 (4h), T2 (12h), T3 (24h). 
-Consumption of analgesics rescue. 
-Incidence of side effects such as shivering, nausea, 
vomiting. 
-Surgical complications: bleeding and bruising, signs of 
infection. 
-Concentrations of serum magnesium were checked 
before practicing anaesthesia, immediately after surgery, 
and at 1 h and 24 h after surgery (normal values at our 
laboratory services = 0.75 to 1 mmol / L). 
    
 
  III. RESULTS  
 
 In case of VAS 6 paracetamol 1 gr iv was 
administered. The postoperative pain scores were 
significantly lower in MS group at 4 h, 12 h, 24 h after 
surgery (p <0.01), the consumption of rescue analgesics 
12 h and 24 h after surgery was also significantly 
decreased (p <0.01) . 
No patient of the MS group requires analgesic 
drugs in the first 4 hours, one patient needed paracetamol 
at time T2 and one at time T3. In SI group we 
administered analgesic drugs one time in the first 4 h, 4 
times in 12 hours and 5 times in 24 hours. 
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Fig. 2. VAS of SI group patients 
 
The serum concentration of MgSO4 has never 
exceeded 1 mmol / L; moreover no side effect of 
hypermagnesemia occurred.  
The hemodynamic changes, the incidence of 
PONV and shivering, the recovery of the motility of the 




  IV.  DISCUSSION 
 
 The postoperative pain after hip replacement is 
usually described as moderate to severe, thus affecting 
patient outcome [13,14]. Although the mechanism is not 
completely understood, magnesium sulphate could 
prevent central sensitization following peripheral 
nociceptive stimulation, and abolish hypersensitivity. This 
analgesic properties are due to its action on NMDA 
receptors and calcium channels.   
The perioperative administration of magnesium 
sulphate [17,18], either in single injection or as a 
continuous infusion, appears to be effective in reducing 
postoperative pain and it is associated with minor 
consumption of analgesic drugs in the first 24 hours, 






  V.  CONCLUSION 
 
 Although carried out on a limited number of 
patients, this study confirms that the iv infusion of 
magnesium sulphate during spinal anaesthesia improves 
the quality of analgesia and reduces the postoperative 
consumption of analgesics. This property is probably 
related to the competitive antagonism on NMDA receptor 
and to the blockade of calcium channels, both involved in 
the mechanisms of central sensitization of pain. 
Magnesium sulphate appears to be safe, free from side 
effects and well tolerated at low dosage. These results 
could provide a basis for further investigation about the 
use of this drug as an important analgesic adjuvant in the 
perioperative period, especially in patients in which 
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